The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Korean scientists have developed a revolutionary eye drop treatment for dry age-related macular degeneration (AMD), potentially eliminating the need for regular eye injections that millions of elderly ...

This article discusses some of the new treatments that are emerging to treat both wet and dry age-related macular degeneration (AMD). Related: Wet vs. Dry Age-Related Macular Degeneration New ...

Worldwide, age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged 50 or older. Neovascular AMD is an advanced form of the condition, also known as “exudative ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and ...

The research team from the Natural Product Drug Development Center at the Korea Institute of Science and Technology has developed a new therapeutic agent for dry Age-related macular ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

Tonabersat (HCB-1019) is under development for the treatment of diabetic macular edema (DME),Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), diabetic nephropathy (DR), dry and wet age-related ...